CANY
RPRX icon

Caxton Associates (New York)’s Royalty Pharma RPRX Stock Holding History

Caxton Associates (New York)’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-42,786
Closed -$1.69M – 617
2022
Q4 		$1.69M Buy
+42,786
New +$1.79M 0.11% 59

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caxton Associates (New York)'s RPRX Position: Q1 2023 in Review

Caxton Associates (New York) sold out of Royalty Pharma (RPRX) in Q1 2023, closing a stake of 42,786 shares — an estimated $1.69M sold.

Caxton Associates (New York) first reported a position in RPRX in Q4 2022 and held it in 1 quarter. The position peaked at $1.69M in Q4 2022. 335 funds tracked by Wall St. Rank hold RPRX as of Q1 2023.

  • Caxton Associates (New York) reported no remaining Royalty Pharma position as of Q1 2023 after selling out during the quarter.
  • Caxton Associates (New York) sold 42,786 Royalty Pharma shares in Q1 2023, an estimated $1.69M.
  • Caxton Associates (New York) first reported a position in Royalty Pharma in Q4 2022 and held it in 1 quarter.
  • Caxton Associates (New York)'s Royalty Pharma position peaked at $1.69M in Q4 2022.
  • 335 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2023.

Based on Caxton Associates (New York)'s 13F filing for Q1 2023, filed 15 May 2023.